#1292ef

Concord Biotech

#f9f9f9

Dr. Jaimini Dave

Anand Dhiman

Kirit Joshi

Satyendra Kr Jha

Jaimini Dave

Vinkal Zalavadiya

Sonal Kumra

Binit Shah

Amit Varma

Amrut Parekh

Ankur Vaid

Sudhir Vaid

Devendra Patel

Rajkumar Awachar

Tejas Pndya

R&D
At Concord, we believe that R&D can be the difference between mediocre results and phenomenal success. Concord has dedicated R&D units for API & Formulation Development. Both the R&D centers are approved by DSIR (Department of Scientific and Industrial Research), India.
R&D a key growth driver for Concord is headed by highly qualified scientists and is equipped with modern equipment. Our continuous R & D initiatives have strengthened our product basket, giving us an edge in manufacturing of niche and complex API?s in Oncology, Immunosuppressant, Antibiotic and, Antifungal segments. Since inception, Concord has launched several breakthrough products in the market and has a robust pipeline of products. The core focus of the API R&D team is in the area of fermentation, semi-synthesis & synthesis based products that comply with the European and US Regulatory standards and guidelines.
Concord is also working on Contract Research & Manufacturing projects with global companies in the area of strain improvement, media optimization and scaling up product from R&D to Pilot and commercial scale (conceptualization to commercialization). R&D is well supported by Analytical Development Laboratory. With Concord?s manufacturing site having global regulatory compliance, our customers have the flexibility to take the project for global filing.
The Formulation R&D team is focused on developing specialty generic formulations in the area of Immunology, Oncology, Hematology, Dermatology, Injectable and Small Volume Parental Forms targeting global filings.
API
R&D BIOTECHNOLOGY
Concord has state of the art Microbiology R&D facility that is certified by DSIR.
API
R&D CHEMICAL
Chemical R&D facility and Analytical Development Laboratory at Concord is equipped with all sophisticated equipments to support the upstream process.
FORMULATION DEVELOPMENT
Concord has setup world class Formulation and Analytical Development Laboratory to develop and commercialize complex niche generic formulations targeting the global markets.
Disclaimer - Important
THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA.
IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.
The following disclaimer applies to the Prospectus of Concord Biotech Limited(the ?Company?) datedAugust 9, 2023(the ?Prospectus?) filed with the Registrar of Companies, Gujarat at Ahmedabad and thereafter with theSecurities and Exchange Board of India (?SEBI?)and the BSE Limited and the National Stock Exchange of India Limited, in relation to the initial public offering of the equity shares of face value of ? 1 each (?Equity Shares?) of the Company (?Offer?).
THE PROSPECTUSIS BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (?SEBI ICDR REGULATIONS?).In accessing the Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.
TheProspectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. No part of the contents of the Prospectus shall be copied or duplicated in any form by any means, or redistributed.
The Prospectus has been hosted on this website as prescribed under Regulation 26 of the SEBI ICDR Regulations. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neitherthe Companynor any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.
The Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdictionand is not intended for distribution to, or use by, any person or entity in any jurisdiction or countrywhere (a) distribution or use of such information would be contrary to law or regulation; or (b) the Companyor any of itsaffiliates would by virtue of such distribution become subject to new or additional registration, licensing or otherregulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the ?U.S.Securities Act?) or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such Equity Shares are being offered and sold (i) outside of the United States in ?offshore transactions? as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) to ?qualified institutional buyers? (as defined in Rule 144A under the U.S. Securities Act) pursuant toSection 4(a) of the U.S. Securities Act.No person outside India is eligible to bid for Equity Shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which comprises the red herring prospectus dated July 27, 2023and the preliminary international wrap (which contains, among other things, the selling restrictions for the Offer outside India).
Any person into whose possession theProspectus comes is required to inform himself or herself about and to observe any such restrictions.
Neither the Company norany of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Companyand its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Prospectus beyond the date of the Prospectus. The information in the Prospectus is as of the date thereof and neither the Company nor its affiliates, directors or employees are under any obligation to update or revise the Prospectus to reflect circumstances arising after the date thereof.
Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, see the section titled ?Risk Factors? of the Prospectus.
The Company and its affiliateswill not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company,any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.
If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access you are located in India. If you cannot make this confirmation, you must press the button marked "I Do Not Confirm".
The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.
I Do Not Confirm I Confirm
Disclaimer - Important
You are not permitted to view the materials in this section of the website.
Disclaimer - Important
THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA.
IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.
The following disclaimer applies to the Red Herring Prospectus of Concord Biotech Limited(the ?Company?) datedJuly 27, 2023(the ?Red Herring Prospectus?) filed with the Registrar of Companies, Gujarat at Ahmedabad and thereafter with theSecurities and Exchange Board of India (?SEBI?)and the BSE Limited and the National Stock Exchange of India Limited, in relation to the initial public offering of the equity shares of face value of ? 1 each (?Equity Shares?) of the Company (?Offer?).
THE RED HERRING PROSPECTUSIS BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (?SEBI ICDR REGULATIONS?).In accessing the Red Herring Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.
TheRed Herring Prospectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Red Herring Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. No part of the contents of the Red Herring Prospectus shall be copied or duplicated in any form by any means, or redistributed.
The Red Herring Prospectus has been hosted on this website as prescribed under Regulation 26 of the SEBI ICDR Regulations. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neitherthe Companynor any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.
The Red Herring Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdictionand is not intended for distribution to, or use by, any person or entity in any jurisdiction or countrywhere (a) distribution or use of such information would be contrary to law or regulation; or (b) the Companyor any of itsaffiliates would by virtue of such distribution become subject to new or additional registration, licensing or otherregulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the ?U.S.Securities Act?) or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such Equity Shares are being offered and sold (i) outside of the United States in ?offshore transactions? as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) to ?qualified institutional buyers? (as defined in Rule 144A under the U.S. Securities Act) pursuant toSection 4(a) of the U.S. Securities Act.No person outside India is eligible to bid for Equity Shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which comprises the Red Herring Prospectus and the preliminary international wrap (which contains, among other things, the selling restrictions for the Offer outside India).
Any person into whose possession theRed Herring Prospectus comes is required to inform himself or herself about and to observe any such restrictions.
Neither the Company norany of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Companyand its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Red Herring Prospectus beyond the date of the Red Herring Prospectus. The information in the Red Herring Prospectus is as of the date thereof and neither the Company nor its affiliates, directors or employees are under any obligation to update or revise the Red Herring Prospectus to reflect circumstances arising after the date thereof.
Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, see the section titled ?Risk Factors? on page 26 of the Red Herring Prospectus.
The Company and its affiliateswill not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company,any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.
If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access you are located in India. If you cannot make this confirmation, you must press the button marked "I Do Not Confirm".
The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.
I Do Not Confirm I Confirm
Disclaimer - Important
You are not permitted to view the materials in this section of the website

Concord Biotech Limited